Save time and get answers to complex questions with AI chat
What are the liver enzyme requirements for starting terbinafineWhen does the apixaban patent expire?Fda livtencity approval letter march 23 2021 regulatory project managerWhen does the patent expire on ibranceAdefovir dipivoxil discount card
See the DrugPatentWatch profile for Nusinersen
Nusinersen is a medicine used to treat spinal muscular atrophy (SMA). It is designed to increase production of the SMN (survival motor neuron) protein that patients with SMA lack or produce at low levels. [1]
Nusinersen works by modifying the splicing of the SMN2 gene so that more functional SMN protein is produced. In SMA, SMN2 largely produces a shortened, less functional form of SMN, so shifting splicing toward the full-length form helps support motor neuron function. [1]
Nusinersen is administered by intrathecal injection, meaning it is delivered into the spinal fluid via the intrathecal route. [1]
Nusinersen is indicated for spinal muscular atrophy. [1]
The provided information does not list specific side effects for nusinersen. [1]
The provided information does not include dosing schedule details. [1]
The provided information only covers nusinersen and does not mention alternatives. [1]
Other Questions About Nusinersen :